Table 2.
Ribavirin/Recombinant Interferon Therapy in Critically Ill Patients With Middle East Respiratory Syndrome
| Variable | No. (%) or Median (Q1, Q3) |
|---|---|
| RBV and/or rIFN | 144 (100) |
| Combination of RBV and rIFN | 117 (81.3) |
| RBV alone | 18 (12.5) |
| rIFN alone | 9 (6.3) |
| rIFN type (n = 126) | |
| rIFN α-2a | 73 (57.9) |
| rIFN α-2b | 22 (17.5) |
| rIFN-β1a | 31 (24.6) |
| Duration between hospital presentation and RBV/rIFN initiation, d | 5.0 (2.0, 9.0) |
| Duration between ICU admission and RBV/rIFN initiation, d | 2.0 (1.0, 3.0) |
| Duration between onset of ventilation and RBV/rIFN initiation, d | 2.0 (1.0, 3.0) |
| Duration between onset of symptoms and RBV/rIFN initiation, d | 9.0 (6.0, 12.0) |
| Duration of treatment, d | 8 (5, 12) |
| Duration of treatment among survivors, d | 9.5 (7.5, 15.0) |
Abbreviations: ICU, intensive care unit; RBV, ribavirin; rIFN, recombinant interferon.